Short Interest in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Rises By 298.4%

by · The Cerbat Gem

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM – Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totaling 16,171 shares, a growth of 298.4% from the November 30th total of 4,059 shares. Currently, 1.3% of the shares of the company are short sold. Based on an average daily trading volume, of 20,878 shares, the short-interest ratio is currently 0.8 days. Based on an average daily trading volume, of 20,878 shares, the short-interest ratio is currently 0.8 days. Currently, 1.3% of the shares of the company are short sold.

Global X Genomics & Biotechnology ETF Trading Down 0.9%

GNOM stock traded down $0.44 during trading on Friday, reaching $47.21. 3,584 shares of the stock were exchanged, compared to its average volume of 14,350. Global X Genomics & Biotechnology ETF has a twelve month low of $27.20 and a twelve month high of $48.09. The company has a market capitalization of $57.60 million, a P/E ratio of -20.18 and a beta of 1.22. The stock has a 50 day simple moving average of $45.11 and a 200-day simple moving average of $39.47.

Institutional Trading of Global X Genomics & Biotechnology ETF

Institutional investors and hedge funds have recently modified their holdings of the company. HighTower Advisors LLC lifted its position in Global X Genomics & Biotechnology ETF by 16.7% in the first quarter. HighTower Advisors LLC now owns 15,242 shares of the company’s stock worth $121,000 after purchasing an additional 2,184 shares during the period. Smartleaf Asset Management LLC raised its stake in shares of Global X Genomics & Biotechnology ETF by 18.5% in the 1st quarter. Smartleaf Asset Management LLC now owns 14,933 shares of the company’s stock valued at $125,000 after buying an additional 2,329 shares in the last quarter. Jane Street Group LLC raised its stake in shares of Global X Genomics & Biotechnology ETF by 7.7% in the 1st quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock valued at $1,143,000 after buying an additional 10,308 shares in the last quarter. Oxinas Partners Wealth Management LLC lifted its holdings in shares of Global X Genomics & Biotechnology ETF by 12.1% during the 2nd quarter. Oxinas Partners Wealth Management LLC now owns 16,212 shares of the company’s stock worth $137,000 after acquiring an additional 1,751 shares during the period. Finally, Halbert Hargrove Global Advisors LLC boosted its position in shares of Global X Genomics & Biotechnology ETF by 182.4% during the 2nd quarter. Halbert Hargrove Global Advisors LLC now owns 13,685 shares of the company’s stock valued at $115,000 after acquiring an additional 8,839 shares in the last quarter. 56.95% of the stock is currently owned by institutional investors.

Global X Genomics & Biotechnology ETF Company Profile

(Get Free Report)

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.

Further Reading